[Abstract Title]. - Society for Neuroscience

References:
1. S. M. Reppert, D. R. Weaver, Nature 418, 935 (Aug 29, 2002).
2. C. B. Saper, T. C. Chou, T. E. Scammell, Trends Neurosci 24, 726 (Dec, 2001).
3. C. B. Saper, J. Lu, T. C. Chou, J. Gooley, Trends Neurosci 28, 152 (Mar, 2005).
4. J. H. Meijer, W. J. Schwartz, J Biol Rhythms 18, 235 (Jun, 2003).
5. S. N. Peirson et al., Curr Biol 17, 1363 (Aug 21, 2007).
Disclosures: S.H. Godinho, F Hoffmann-La Roche, B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as grants already received); R. Butler, F
Hoffmann-La Roche, B. Research Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received); M. Ebling, F Hoffmann-La Roche, A.
Employment (full or part-time); S. Gatti, F Hoffmann-La Roche, A. Employment (full or parttime);
J.G. Wettstein, F Hoffmann-La Roche, A. Employment (full or part-time); M. Hankins,
F Hoffmann-La Roche, B. Research Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received); R. Foster, F Hoffmann-La Roche, B.
Research Grant (principal investigator, collaborator or consultant and pending grants as well as
grants already received); S. Peirson, F Hoffmann-La Roche, B. Research Grant (principal
investigator, collaborator or consultant and pending grants as well as grants already received).
Poster
285. Sleep: Molecular, Cellular and Pharmacology I
Time: Sunday, November 16, 2008, 1:00 pm - 5:00 pm
Program#/Poster#: 285.11/QQ27
Topic: E.08.c. Sleep: Molecular, cellular, and pharmacology
Support: Cephalon, Inc.
Title: Biochemical, pharmacological, and behavioral characterization of the dopaminergic
stimulant sydnocarb in rats
Authors: *J. A. GRUNER, D. G. FLOOD, J. R. MATHIASEN, L. D. AIMONE, M. J.
MARINO, M. GASIOR;
CNS Biol., Cephalon, Inc, West Chester, PA
Abstract: Sydnocarb is a psychomotor stimulant structurally similar to amphetamine that has
been used in Russia since the 1970s for the treatment of a variety of neuropsychiatric
comorbidities (e.g., asthenia, apathy, and adynamia). It has been reported to have lower toxicity
and abuse potential than prototypical dopaminergic psychostimulants such as cocaine and
amphetamine. Microdialysis studies have revealed sydnocarb-induced facilitation of